GNCC Capital, Inc. (OTCPK: GNCP)
Health Care · Pharmaceuticals · US
$0.00
-99.00% today · 0.0% 1Y
GNCC Capital, Inc. (OTCPK: GNCP) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $174.15K and employs 900 people.
Over the last twelve months the share price has gained 0.0%, trading between 0.00 and 0.00.
Tweenvest scores GNCC Capital, Inc. across four factors: quality 16/100. Its strongest factor is quality.
GNCP price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $174.15K
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.01
- Dividend yield
- —
- Beta (5Y)
- -33.75
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 174.14B
- Employees
- 900
- Next earnings
- —
About GNCC Capital, Inc.
GNCC Capital, Inc., operating through its subsidiary BioCann Pharma S.A.S., specializes in the production and marketing of pharmaceutical-grade CBD oils derived from cannabis. These products are distributed via established networks throughout Colombia and across the broader Latin American market. The parent company's headquarters are located in Las Vegas, Nevada.
- ISIN
- US38013E2037
- Listed since
- Sep 1, 2009
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF375.40 | +0.43% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £123.86 | -0.72% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.